Gilead Sciences will distribute remdesivir as a coronavirus drug at $2,340 per patient and the U.S. is expected to be the first country to get most of the company's supply.Original Article
You may also like
Ninth Circuit Upholds FDA’s Authority to Regulate...
Skinny-Label Lives to See Another Day
Bring Out Your Meds! Bring Out Your Meds!
Homeopathic Industry Group Wants Court to Exclude It...
A Reversal on Sequencing? Proposed Legislation Would...
FDA Guidance Outlines a Framework for the Evaluation...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.